Pradaxa stormed the market in 2010 and was widely prescribed as an anticoagulant drug used to prevent or treat blood clots.  Initially, it seemed effective at reducing the risk of stroke, particularly in patients with atrial fibrillation. The manufacturer, German-based Boehringer Ingelheim Pharmaceuticals, Inc., has realized more than $ 1 billion in sales from the

As, we have previously reported, the number of Pradaxa lawsuits continues to grow across the country.  The number of lawsuits has increased by nearly 17% in recent months and now approaches 200 nationwide.

The medication resource center, DrugRisk, continues to receive, organize and disseminate safety issues relating to Pradaxa.  New reports indicate Pradaxa is

The number of Pradaxa lawsuits continues to grow across the country. According to recent reports, there are currently 176 cases pending in federal court with more expected to follow. Unfortunately, individuals continue to experience negative effects from the drug including uncontrollable bleeding. Unlike its competitor Coumadin, known generically as Warfarin, developers were unable to create

According to recent reports, patients that are taking the anti-clotting drug Pradaxa have a 33% higher risk of heart attack or severe symptoms of heart disease than patients taking Warfarin. The finding, from Cleveland Clinic researchers Ken Uchino, MD, and Adrian V. Hernandez, MD, PhD, is based on data from seven clinical trials that enrolled

The blood thinner mediation Pradaxa is generally prescribed to prevent strokes among patients with irregular heartbeats. In September 2011, the drug became the subject of an investigation in New Zealand after as many as five elderly Pradaxa patients reportedly died as a result of internal bleeding/ hemorrhaging. Another 36 Pradaxa patients reportedly suffered bouts of

Pradaxa (dabigatran etexilate mesylate) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in October 2010, to prevent strokes among patients with atrial fibrillation (irregular heartbeat).

In the last quarter of 2010 alone, the FDA received over 300 complaints about the side effects of Pradaxa. In November 2011, Boehringer,

The FDA-approved blood thinner mediation Pradaxa is quickly becoming one of the leading stroke prevention therapies in the atrial fibrillation drug market. However, it has been reported that the risk of internal bleeding associated with Pradaxa is five (5) times higher than originally estimated.

Some symptoms of Pradaxa side effects include lethargy, unusual bruising or